A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients

A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients

Objective: To assess the safety and efficacy of the endothelin receptor antagonist ambrisentan in pediatric pulmonary arterial hypertension (PAH). Study design: In this open-label, phase IIb study, patients with PAH aged 8 to <18 years were randomized to low- or high-dose ambrisentan for 24 weeks...

Full description

Bibliographic Details
Main Authors: Dunbar Ivy, MD, Maurice Beghetti, MD, Ernesto Juaneda-Simian, MD, PhD, Diane Miller, PhD, Mary Ann Lukas, MD, Chris Ioannou, PhD, Malek Okour, PhD, Jun Narita, MD, Rolf M.F. Berger, MD, PhD
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:The Journal of Pediatrics: X
Subjects:
clinical trial
endothelin receptor antagonist
cardiovascular disease
treatment
children
Online Access:http://www.sciencedirect.com/science/article/pii/S2590042020300367

Internet

http://www.sciencedirect.com/science/article/pii/S2590042020300367

Similar Items